tbuckley/cabot-search huggingface dataset:
Intrahepatic mitomycin C infusion in breast cancer liver metastases
Authors: B. Aarts, E. Klompenhouwer, R. Dresen, A. Laenen, R. Beets-Tan, K. Punie, P. Neven, G. Maleux, H. Wildiers
Journal: Annals of Oncology (2019)

Background: The aim of this study was to determine the safety and efficacy of intrahepatic Mitomycin C (MMC) infusion in patients with advanced metastatic breast cancer (mBC) resistant to systemic chemotherapy with liver dominant metastatic disease. We determined factors influencing overall survival. Methods: We retrospectively analysed patients with mBC, treated with MMC infusion between 2000 and 2017. Hepatic response was measured by comparing CT scans after MMC infusion with baseline CT scans according to response evaluation criteria in solid tumours (RECIST) 1.1. Toxicities were registered by the common toxicity criteria for adverse events (CTCae) version 5.0. Overall survival (OS) and hepatic progression free survival (hPFS) were evaluated using Kaplan Meier estimates. After univariable analysis, a stepwise forward multivariable (MV) prediction model was developed to select independent pre-treatment factors associated with OS. Results: We included 176 patients who received a median of 4 prior lines of systemic therapy for mBC. The median time from diagnosis of mBC to first MMC infusion was 36.9 months (SD 35.6). RECIST evaluation of liver lesions (n = 132) after 1-3 of MMC infusions showed a partial response rate of 20%, stable disease of 57% and progressive disease in 23%. CTCae toxicity grade 3 and 4 were reported in 17.5%. Median PFS was 5.5 months and median OS was 7.8 months. Significant independent baseline predictors of worse OS on MV analysis included amount of prior systemic chemotherapy (HR = 1.2 CI;1.1-1.3), prior liver ablation (HR = 5.9 CI;1.8-19.4), higher liver tumour burden (HR = 2.4 CI;1.5-3.7), elevated levels of bilirubin (HR = 2.18 CI;1.3-3.8) and ALT (HR = 1.5 CI;1.01-2.09). Conclusions: MMC infusion was safe and effective in patients with advanced mBC. MV analysis showed a worse OS in patients with increased amount of prior systemic chemotherapy, prior liver ablation, higher liver tumour burden and elevated levels of bilirubin and ALT. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Injectable Cholesterol‐Enhanced Stereocomplex Polylactide Thermogel Loading Chondrocytes for Optimized Cartilage Regeneration
Authors: Chenyu Wang, Naibo Feng, Fei Chang, Jincheng Wang, Baoming Yuan, Yilong Cheng, He Liu, Jiakuo Yu, Jun Zou, Jianxun Ding, Xuesi Chen
Journal: Advanced Healthcare Materials (2019)

Abstract Ideal cartilage tissue engineering requires scaffolds featuring good biocompatibility, large pore structure, high mechanical strength, as well as minimal invasion procedure. Although significant progress has been made in the development of polymer scaffolds, the construction of smart systems with all the desired properties is still emerging as a challenge. The thermogels of stereocomplex 4‐arm poly(ethylene glycol)–polylactide (PEG–PLA) (scPLA gel ) and stereocomplex cholesterol‐modified 4‐arm PEG–PLA (scPLA–Chol gel ) from the equimolar enantiomeric 4‐arm PEG–PLA and 4‐arm PEG–PLA–Chol, respectively, are fabricated as scaffolds for cartilage tissue engineering. scPLA–Chol gel shows lower critical gelation temperature, higher mechanical strength, larger pore size, better chondrocyte adhesion, and slower degradation compared to scPLA gel as the benefit of cholesterol modification, which is more appropriate for cartilage regeneration. Moreover, the preservation of morphology, biomechanical property, cartilaginous specific matrix, as well as cartilaginous gene expressions of engineered cartilage mediated by scPLA–Chol gel are proven superior to those by scPLA gel . scPLA–Chol gel serves as a promising chondrocyte carrier for cartilage tissue engineering and gives an alternative solution to clinical cartilage repair.
Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer
Authors: Smith Giri, Scott F. Huntington
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma
Authors: Andrea Anichini
Journal: Cancer Research (2019)

Abstract Gene signatures are increasingly being used to infer the immune composition of the tumor microenvironment. This strategy holds the promise for earlier detection, identification of patients at higher risk of progression, and for understanding therapeutic response and resistance to immunotherapy. This gene signature approach is now being integrated with information from genomic changes, gene networks, and master immunoregulatory genes, and this development can lead to identify the main determinants shaping the tumor immune landscape. A study in this issue of Cancer Research indicates a way forward to discover prognostic immune-related subsets in primary melanoma and to understand major determinants impairing protective immunity in early stage of disease. See related article by Poźniak et al., p. 2684
Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Authors: Shuiying Hu, Kevin M. Huang, Elizabeth J. Adams, Charles L. Loprinzi, Maryam B. Lustberg
Journal: Clinical Cancer Research (2019)

Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting toxicity, negatively affecting both quality of life and disease outcomes. To date, there is no proven preventative strategy for CIPN. Although multiple randomized trials have evaluated a variety of pharmacologic interventions for the treatment of CIPN, only duloxetine has shown clear efficacy in a phase III study. The National Cancer Institute's Symptom Management and Health-Related Quality of Life Steering Committee has identified CIPN as a priority for translational research in cancer care. Promising advances in preclinical research have identified several novel preventative and therapeutic targets, which have the potential to transform the care of patients with this debilitating neurotoxicity. Here, we provide an overarching view of emerging strategies and therapeutic targets that are currently being evaluated in CIPN.
Replication-Independent Histone Turnover Underlines the Epigenetic Homeostasis in Adult Heart
Authors: Yumei Li, Shanshan Ai, Xianhong Yu, Chen Li, Xin Li, Yanzhu Yue, Yusheng Wei, Chuan-Yun Li, Aibin He
Journal: Circulation Research (2019)

Rationale: Replication-independent histone turnover has been linked to cis-regulatory chromatin domains in cultured cell lines, but its molecular underpinnings and functional relevance in adult mammalian tissues remain yet to be defined. Objective: We investigated regulatory functions of replication-independent histone turnover in chromatin states of postmitotic cardiomyocytes from adult mouse heart. Methods and Results: We used H2B-GFP (histone 2B-green fluorescent protein) fusion protein pulse-and-chase approaches to measure histone turnover rate in mouse cardiomyocytes. Surprisingly, we found that the short histone half-life (≈2 weeks) contrasted dramatically with the long lifetime of cardiomyocytes, and rapid histone turnover regions corresponded to cis-regulatory domains of heart genes. Interestingly, recruitment of chromatin modifiers, including Polycomb EED (embryonic ectoderm development), was positively correlated with histone turnover rate at enhancers. Mechanistically, through directly interacting with and engaging the BAF (BRG1 [Brahma-related gene-1]-associated factor) complex for nucleosome exchange for stereotyped histone modifications from the free histone pool, EED augmented histone turnover to restrain enhancer overactivation. Conclusions: We propose a model in which replication-independent histone turnover reinforces robustness of local chromatin states for adult tissue homeostasis.
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
Authors: Jean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, Mradul Kumar Daga, Jean-Baptiste Lascarrou, Mikhail Y. Kirov, Ville Pettilä, Xavier Wittebole, Ferhat Meziani, Emmanuelle Mercier, Suzana M. Lobo, Philip S. Barie, Mark Crowther, Charles T. Esmon, Jawed Fareed, Satoshi Gando, Kenneth J. Gorelick, Marcel Levi, Jean-Paul Mira, Steven M. Opal, Joseph Parrillo, James A. Russell, Hidehiko Saito, Kazuhisa Tsuruta, Takumi Sakai, David Fineberg
Journal: JAMA (2019)

Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy.To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy.The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 × 109/L or a greater than 30% decrease in platelet count within 24 hours, were considered for inclusion. The final date of follow-up was February 28, 2019.Patients with sepsis-associated coagulopathy were randomized and treated with an intravenous bolus or a 15-minute infusion of thrombomodulin (0.06 mg/kg/d [maximum, 6 mg/d]; n = 395) or matching placebo (n = 405) once daily for 6 days.The primary end point was 28-day all-cause mortality.Among 816 randomized patients, 800 (mean age, 60.7 years; 437 [54.6%] men) completed the study and were included in the full analysis set. In these patients, the 28-day all-cause mortality rate was not statistically significantly different between the thrombomodulin group and the placebo group (106 of 395 patients [26.8%] vs 119 of 405 patients [29.4%], respectively; P = .32). The absolute risk difference was 2.55% (95% CI, -3.68% to 8.77%). The incidence of serious major bleeding adverse events (defined as any intracranial hemorrhage; life-threatening bleeding; or bleeding event classified as serious by the investigator, with administration of at least 1440 mL [typically 6 units] of packed red blood cells over 2 consecutive days) was 23 of 396 patients (5.8%) in the thrombomodulin group and 16 of 404 (4.0%) in the placebo group.Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality.ClinicalTrials.gov Identifier: NCT01598831.
Place de l'endoscopie interventionnelle dans la prise en charge des fistules après gastric bypass
Authors: A Hijara, R Caiazzo, R Gérard, G Longo, B Pariente, H Verkindt, F Torres, G Baud, V Maunoury, F Pattou, J Branche
Journal: Endoscopy (2019)

Le recours à la chirurgie bariatrique est en constante augmentation. La prise en charge des complications postopératoires est multidisciplinaire et la place de l'endoscopie digestive diagnostique et thérapeutique mal définie. La fistule complique 1% des gastric bypass. Elle est accessible à un traitement endoscopique selon plusieurs stratégies. Il n'existe cependant pas de recommandation de prise en charge de la fistule après gastric bypass.
Subsetting reveals CD16<sup>high</sup> CD62L<sup>dim</sup> neutrophils in chronic rhinosinusitis with nasal polyps
Authors: Julia Arebro, Cecilia Drakskog, Ola Winqvist, Claus Bachert, Susanna Kumlien Georén, Lars‐Olaf Cardell
Journal: Allergy (2019)

The authors have no conflicts to declare. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Why Bolstering Trust in Journalism Could Help Strengthen Trust in Medicine
Authors: Vineet M. Arora, David Rousseau, Gary Schwitzer
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Les résultats de la myotomie oesophagienne per orale endoscopique (POEM) dans l'achalasie de l'oesophage sont-ils différents chez les patients naïfs et les patients en échec des autres traitements? Résultats d'une étude multicentrique sur 101 patients
Authors: R Olivier, C Brochard, L Quénéhervé, T Wallenhorst, G David, F Douane, J Podevin, C Silvain, S Bruley des Varannes, A Ropert, E Coron
Journal: Endoscopy (2019)

La myotomie per orale endoscopique (POEM) fait partie de l'arsenal thérapeutique moderne de la prise en charge de l'achalasie. Son efficacité a été largement démontrée et elle est désormais souvent proposée en traitement de première intention. Néanmoins, l'impact global des traitements antérieurs sur les résultats de cette intervention reste à déterminer en pratique courante. Le but de notre étude était donc de comparer la faisabilité, la morbidité et l'efficacité de la POEM chez les patients naïfs et non naïfs.
SINGLE-SESSION EUS-GUIDED CHOLECYSTODUODENOSTOMY AND TRANSCYSTIC RENDEZVOUS AS RESCUE OF FAILED ERCP BILIARY ACCESS
Authors: R Sanchez-Ocaña, A Yaiza Carbajo, S Bazaga, M de Benito, FJ García-Alonso, C de la Serna Higuera, M Pérez-Miranda
Journal: Endoscopy (2019)

EUS-guided rendez-vous (EUS-RV) carries a 30% failure rate. Several transluminal endoscopic interventions within the gallbladder (GB) via EUS-guided anastomoses have recently been reported in non-surgical patients with prior EUS-guided GB drainage (EUS-GBD). We report single-session EUS-guided cholecystoduodenostomy and transduodenal cholecystoscopy aiming at transcystic RV to overcome failed ERCP.
Transmission risk of avian influenza virus along poultry supply chains in Guangdong, China
Authors: Jian-Yong Wu, Eric HY Lau, Jun Yuan, Ming-Ling Lu, Chao-Jun Xie, Kui-Biao Li, Xiao-Wei Ma, Jian-Dong Chen, Yan-Hui Liu, Lan Cao, Mei-Xia Li, Biao Di, Yu-Fei Liu, Jian-Yun Lu, Tie-Gang Li, Xin-Cai Xiao, Da-Hu Wang, Zhi-Cong Yang, Jia-Hai Lu
Journal: Journal of Infection (2019)
The Benefits and Risks of Iron Supplementation in Pregnancy and Childhood
Authors: Michael K. Georgieff, Nancy F. Krebs, Sarah E. Cusick
Journal: Annual Review of Nutrition (2019)

Iron deficiency is the most common micronutrient deficiency in the world and disproportionately affects pregnant women and young children. Iron deficiency has negative effects on pregnancy outcomes in women and on immune function and neurodevelopment in children. Iron supplementation programs have been successful in reducing this health burden. However, iron supplementation of iron-sufficient individuals is likely not necessary and may carry health risks for iron-sufficient and potentially some iron-deficient populations. This review considers the physiology of iron as a nutrient and how this physiology informs decision-making about weighing the benefits and risks of iron supplementation in iron-deficient, iron-sufficient, and iron-overloaded pregnant women and children.
For Fat Burning, Interval Training Beats Continuous Exercise
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FACTORS ASSOCIATED TO WOPN ENDOSCOPIC TREATMENT SUCCESS
Authors: L González, A Brujats, M Trias, B De Riba, R Romito, M Murzi, J Colan, M Concepción, J Gordillo, JC Pernas, M Poca, G Soriano, C Guarner Argente
Journal: Endoscopy (2019)

Endoscopic necrosectomy with metal stents, especially lumen apposition metal stents (LAMS), is increasingly being used for the treatment of complicated walled-off pancreatic necrosis (WOPN), but the need for necrosectomy is not well understood. The aim of this study is to evaluate clinical, endoscopic and radiologic predictors for the need of necrosectomy in patients treated with LAMS.
COMPLIANCE WITH INSTRUCTIONS OF USE FOR ORAL SULPHATE SOLUTION, TOLERABILITY AND SAFETY IN A REAL-LIFE SETTING: A EUROPEAN MULTICENTRE POST-AUTHORISATION SAFETY STUDY
Authors: J Regula, MCW Spaander, S Suchanek, A Kornowski, V Perrot, W Fischbach
Journal: Endoscopy (2019)

Oral Sulphate Solution (OSS) is a low-volume bowel cleansing solution administered as 2 doses of 500 ml saline sulphate solution each followed by 1000 ml water or clear liquids (for hydration). The aim of this study was to assess non-compliance with hydration guidelines and describe the safety profile of OSS in routine practice.
Predictors of hospital discharge in cancer patients with pericardial who undergosurgical pericardial drainage
Authors: Ricardo Mingarini Terra, Pedro Henrique Xavier Nabuco de Araújo, Thamara Kazantzis, Leticia Leone Lauricella, Alberto Jorge Monteiro Dela Vega, Benoit Bibas, Paulo Manuel Pego-Fernandes
Journal: Journal of Thoracic Oncology (2014)
Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity
Authors: Pei-Ju Sung, Nicolas Rama, Jeromine Imbach, Stephany Fiore, Benjamin Ducarouge, David Neves, Huei-Wen Chen, David Bernard, Pan-Chyr Yang, Agnès Bernet, Stephane Depil, Patrick Mehlen
Journal: Cancer Research (2019)

Netrin-1 is upregulated in a large fraction of human neoplasms. In multiple animal models, interference with netrin-1 is associated with inhibition of tumor growth and metastasis. Although netrin-1 upregulation was initially described in cancer cells, we report here that in the human colorectal cancer database, the expression of netrin-1 and its receptor UNC5B correlates with a cancer-associated fibroblasts (CAF) signature. Both colon and lung CAF secreted netrin-1 when cocultured with respective cancer cells, and netrin-1 upregulation in CAF was associated with increased cancer cell stemness. Pharmacologic inhibition of netrin-1 with a netrin-1-mAb (Net1-mAb) abrogated the CAF-mediated increase of cancer stemness both in coculture experiments and in mice. Net-1-mAb inhibited intercellular signaling between CAF and cancer cells by modulating CAF-mediated expression of cytokines such as IL6. Together these data demonstrate that netrin-1 is upregulated not only in cancer cells but also in cancer-associated stromal cells. In addition to its direct activity on cancer cells, inhibition of netrin-1 may reduce proneoplastic CAF-cancer cell cross-talk, thus inhibiting cancer plasticity. SIGNIFICANCE: Netrin-1, a navigation cue during embryonic development, is upregulated in cancer-associated fibroblasts and regulates cancer cell stemness.
Changes in colorectal cancer incidence in seven high-income countries: a population-based study
Authors: Marzieh Araghi, Isabelle Soerjomataram, Aude Bardot, Jacques Ferlay, Citadel J Cabasag, David S Morrison, Prithwish De, Hanna Tervonen, Paul M Walsh, Oliver Bucher, Gerda Engholm, Christopher Jackson, Carol McClure, Ryan R Woods, Nathalie Saint-Jacques, Eileen Morgan, David Ransom, Vicky Thursfield, Bjørn Møller, Suzanne Leonfellner, Marianne G Guren, Freddie Bray, Melina Arnold
Journal: The Lancet. Gastroenterology & hepatology (2019)
Clonal Isolation of Human Pluripotent Stem Cells on Nanofibrous Substrates Reveals an Advanced Subclone for Cardiomyocyte Differentiation
Authors: Leqian Yu, Junjun Li, Itsunari Minami, Xiang Qu, Shigeru Miyagawa, Nanae Fujimoto, Kouichi Hasegawa, Yong Chen, Yoshiki Sawa, Hidetoshi Kotera, Li Liu
Journal: Advanced Healthcare Materials (2019)

Abstract Human pluripotent stem cells (hPSCs) have been widely used for various applications including disease modeling and regenerative medicine, among others. Recently, an increasing number of studies has focused on heterogeneity among hPSCs, which could affect cell quality and subsequent applications. In this study, a nanofibrous platform is developed for single human induced pluripotent stem cell isolation and culture. One type of single cell‐derived subclone is established and found to have a distinct morphology compared to other subclones. When used for differentiation toward cardiomyocytes, this type of subclone demonstrates higher differentiation efficiency, increased maturation, and stronger beating compared to those derived from the other subclones. The findings provide a convenient method for single‐cell isolation and culture, and demonstrate that variations in differentiation tendencies exist among subclones from the same cell line. This substrate adhesion‐based selection process could be used to obtain cell lines with improved differentiation efficiency toward cardiomyocytes and other cell types, which would be advantageous for studies in various fields.